The Working Capital Forum
  • Home
  • Events
  • News
  • Features
  • About
  • Login / Register
  • Working Capital Award Winners 2022
  • Home
  • Events
  • News
  • Features
  • About
  • Login / Register
  • Working Capital Award Winners 2022
Search


​FEATURES

Excess Working Capital in Pharmaceuticals has risen 24% to €51 Billion in two years

4/5/2016

 
Picture
Brian Shanahan of Informita (right) sets out the findings of his latest survey of working capital in the pharmaceutical sector
When we published our first pharmaceutical industry working capital analysis in 2012, the survey suggested that there was excess working capital across the industry of €51 billion.

The equivalent survey based in 2014 suggest that excess working capital had reduced to €41 billion, but this latest survey shows a return to to the €51 billion level last seen four years ago.

This would have the effect of reducing the industry average of net working capital to sales from 22% to 13%  –  enough to fund a number of massive acquisitions.

The strangest thing about these numbers is that there has been no uniform deterioration in any element of working capital and there have been several improvers. The most curious piece seems to be that although many pharmaceutical companies make use of financial instruments to manage working capital, the impact of such instruments seems to be limited at best.

Almost all pharmaceutical companies have either a formal working capital programme or someone who is permanently responsible for working capital. The numbers would suggest that only some of these initiatives have been successful, some that were successful have slipped back to a lower level of performance and most have been successful in one area of working capital while under-performing in others.

The number of people working at pharmaceutical companies with titles suggesting a direct responsibility for working capital continues to increase and many of these new recruits are ex-consultants or ex-pharma executives where you would expect a deep experience of both the industry and the techniques required to improve working capital. But it doesn’t seem to be making that much difference for many firms.

With the continued pressure from shareholders to maintain and increase dividends the battle to control working capital continues.

Read the full Informita Pharmaceutical Analysis

Comments are closed.

    Archives

    January 2023
    November 2022
    October 2022
    May 2022
    January 2022
    November 2021
    October 2021
    September 2021
    May 2021
    April 2021
    March 2021
    July 2020
    June 2020
    May 2020
    December 2019
    November 2019
    November 2018
    September 2018
    April 2018
    November 2017
    October 2017
    June 2017
    December 2016
    June 2016
    May 2016
    April 2016
    February 2016
    September 2015
    June 2015
    April 2015

    RSS Feed

WORKING CAPITAL FORUM
FEATURES
NEWS
EVENTS
AWARDS
CONTACT
​admin@workingcapitalforum.com
© ADAUGEO MEDIA LTD 2022
​​PRIVACY POLICY
  • Home
  • Events
  • News
  • Features
  • About
  • Login / Register
  • Working Capital Award Winners 2022